Context Therapeutics Inc. (CNTX)

USD 1.22

(-5.43%)

Market Cap (In USD)

91.49 Million

Revenue (In USD)

-

Net Income (In USD)

-23.96 Million

Avg. Volume

114.17 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.89-2.75
PE
-
EPS
-
Beta Value
2.246
ISIN
US21077P1084
CUSIP
21077P108
CIK
1842952
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Martin A. Lehr
Employee Count
-
Website
https://www.contexttherapeutics.com
Ipo Date
2021-10-20
Details
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.